Halozyme Therapeutics (HALO) Total Debt Growth (5y) (2018 - 2026)
Halozyme Therapeutics (HALO) Total Debt Growth (5y) (2018 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
| 10 |
Halozyme Therapeutics |
8.24 Bn |
7.92 Bn |
297.47 Mn |
| Date | Value |
|---|
| Mar 31, 2026 |
88.95% |
| Dec 31, 2025 |
40.08% |
| Mar 31, 2025 |
250.27% |
| Dec 31, 2024 |
138.43% |
| Sep 30, 2024 |
94.14% |
| Jun 30, 2024 |
84.19% |
| Mar 31, 2024 |
76.89% |
| Dec 31, 2023 |
74.94% |
| Sep 30, 2023 |
76.06% |
| Jun 30, 2023 |
76.65% |
| Mar 31, 2023 |
78.50% |
| Dec 31, 2022 |
81.15% |
| Sep 30, 2022 |
89.58% |
| Jun 30, 2022 |
16.83% |
| Mar 31, 2022 |
24.78% |
| Dec 31, 2021 |
119.02% |
| Sep 30, 2021 |
48.42% |
| Jun 30, 2021 |
93.49% |
| Mar 31, 2021 |
26.57% |
| Dec 31, 2020 |
78.60% |
